NVP-QBE170
NVP-QBE170 is a selective Epithelial sodium channel (ENaC) inhibitor with an IC50 of 57.5 nM. NVP-QBE170 potently inhibits ENaC function in HBECs and shows a longer duration of action. NVP-QBE170 significantly attenuates ENaC activity in the airways of guinea pig models. NVP-QBE170 can be used for hyperkalaemia research[1].
Product Specifications
CAS Number
[1080018-61-6]
UNSPSC
12352100
Target
Sodium Channel
Related Pathways
Membrane Transporter/Ion Channel
Field of Research
Metabolic Disease
Smiles
O=C(C1=NC(Cl)=C(N)N=C1N)NC(NC2CCN(CC2)C(C3=CC=C(C(N4CCC(CC4)NC(NC(C5=NC(Cl)=C(N)N=C5N)=O)=N)=O)C=C3)=O)=N
Molecular Formula
C30H36Cl2N16O4
Molecular Weight
755.62
References & Citations
[1]Coote KJ, et al. NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia. Br J Pharmacol. 2015 Jun;172 (11) :2814-26.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6258605-01 0.1 mL
GMP-1 (Gap Modifying Protein 1, SUMO-1) (FITC)
Sign In for Pricing
View Details MBS6258605-02 5x 0.1 mL
GMP-1 (Gap Modifying Protein 1, SUMO-1) (FITC)
Sign In for Pricing
View Details 132864-ML550 100 µL
RSK1 (Ribosomal S6 Kinase 1, RSK-1, 90kD Ribosomal Protein S6 Kinase 1, p90-RSK 1, p90RSK1, p90S6K, MAP Kinase-activated Protein Kinase 1a, MAPK-activated Protein Kinase 1a, MAPKAP Kinase 1a, MAPKAPK1A, MAPKAPK-1a, Ribosomal Protein S6 Kinase alpha-1, RPS6KA1, S6K-alpha-1) (MaxLight 550)
Sign In for Pricing
View Details